Who are Anti-CD25 mAb's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): Peg-IFN + WB RBV for 24 weeks, Hydroxychloroquine reduced, injectable MS DMT, Glatiramer acetate (GA), herbal immunomodulator, Hydroxychloroquine Sulfate Loading Dose.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/anti-cd25-mab.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-14 · How we verify

Anti-CD25 mAb — Competitive Intelligence Brief

Anti-CD25 mAb (Anti-CD25 mAb) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Monoclonal antibody; immunomodulator. Area: Oncology; Immunology.

phase 3 Monoclonal antibody; immunomodulator CD25 (IL-2 receptor alpha chain) Oncology; Immunology Small molecule Live · refreshed every 30 min

Target snapshot

Anti-CD25 mAb (Anti-CD25 mAb) — Peking University People's Hospital. Anti-CD25 monoclonal antibody binds to the IL-2 receptor alpha chain (CD25) on activated T cells, depleting or inhibiting regulatory T cells and activated effector T cells.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target
Anti-CD25 mAb TARGET	Anti-CD25 mAb	Peking University People's Hospital	phase 3	Monoclonal antibody; immunomodulator	CD25 (IL-2 receptor alpha chain)
Peg-IFN + WB RBV for 24 weeks	Peg-IFN + WB RBV for 24 weeks	National Taiwan University Hospital	marketed	Immunomodulator + nucleoside analog antiviral combination	Interferon-alpha receptor (IFNAR); HCV RNA-dependent RNA polymerase
Hydroxychloroquine reduced	Hydroxychloroquine reduced	University of Sao Paulo General Hospital	marketed	Antimalarial immunomodulator	Lysosomal function; TLR signaling
injectable MS DMT	injectable MS DMT	Biogen	marketed	Immunomodulator (disease-modifying therapy)
Glatiramer acetate (GA)	Glatiramer acetate (GA)	Teva Branded Pharmaceutical Products R&D, Inc.	marketed	Immunomodulator; disease-modifying therapy (DMT)
herbal immunomodulator	herbal immunomodulator	Tatyasaheb Kore Dental College	marketed	Herbal immunomodulator
Hydroxychloroquine Sulfate Loading Dose	Hydroxychloroquine Sulfate Loading Dose	Government of Punjab, Specialized Healthcare and Medical Education Department	marketed	Antimalarial immunomodulator	Toll-like receptors (TLR), lysosomal pH modulation

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Monoclonal antibody; immunomodulator class)

Peking University People's Hospital · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Anti-CD25 mAb — Competitive Intelligence Brief. https://druglandscape.com/ci/anti-cd25-mab. Accessed 2026-05-14.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab